Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLRMT | O00411 | 1/20 | 0.34 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15899087 | 0.82 | ALDH1A1 (0.33) | ALDH1A1MEN1USP2POLBKMT2A | |
| SCHEMBL10148679 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MEN1USP2POLBKMT2A | |
| SCHEMBL16480684 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MEN1USP2POLBKMT2A | |
| SCHEMBL881460 | 0.78 | ALDH1A1 (0.38) | ALDH1A1MEN1USP2POLBKMT2A | |
| SCHEMBL15898728 | 0.76 | POLRMT (0.33) | POLRMT | |
| SCHEMBL17129844 | 0.76 | ALDH1A1 (0.36) | ALDH1A1MEN1USP2POLBKMT2A | |
| SCHEMBL13471034 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MEN1USP2POLBKMT2A | |
| SCHEMBL16085353 | 0.72 | ALDH1A1 (0.44) | ALDH1A1MEN1USP2POLBKMT2A | |
| SCHEMBL12253888 | 0.71 | HPGD (0.35) | — | |
| SCHEMBL16502866 | 0.71 | HPGD (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206640-A1 | 2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ADAR, SLC29A1, SLC28A1 | ALDH1A1 271/4885MEN1 4178/4885USP2 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.